Free Trial

VYNE Therapeutics Q2 2023 Earnings Report

VYNE Therapeutics logo
$2.50 +0.11 (+4.60%)
(As of 12/20/2024 05:40 PM ET)

VYNE Therapeutics EPS Results

Actual EPS
-$3.08
Consensus EPS
-$1.99
Beat/Miss
Missed by -$1.09
One Year Ago EPS
N/A

VYNE Therapeutics Revenue Results

Actual Revenue
$0.14 million
Expected Revenue
$0.10 million
Beat/Miss
Beat by +$40.00 thousand
YoY Revenue Growth
N/A

VYNE Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

VYNE Therapeutics Earnings Headlines

VYNE Therapeutics Inc.
Wall Street Icon: “You must get on the right side of this thing”
I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.
VYNE Therapeutics initiated with a Buy at BTIG
VYNE Therapeutics initiated with a Buy at BTIG on I&I potential
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024
See More VYNE Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VYNE Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VYNE Therapeutics and other key companies, straight to your email.

About VYNE Therapeutics

VYNE Therapeutics (NASDAQ:VYNE), a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

View VYNE Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings